Skip to main content
. 2021 Dec 30;11:24507. doi: 10.1038/s41598-021-04298-1

Figure 5.

Figure 5

NanoSpot adaptation to emerging SARS-CoV-2 variants. (a) SyproRuby-stained SDS PAGE of ~ 20 µg of NanoSpike N501Y, which was expressed in Expi293F cells and purified by one-step affinity purification. Protein yield from 25 ml of Expi293F-cell cultures was 2.5 mg. Defined amounts of BSA are shown for comparison. (b) Hemagglutination assay based on samples from a convalescent COVID-19-patient that was treated with indicated proteins. Three dilutions of the serum and three time points were used to reveal potential differences in agglutination activity.